Philippe Busque - 20 Mar 2024 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
21 Mar 2024, 18:19:39 UTC
Prior SEC filing
08 Mar 2024
Next SEC filing
22 May 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Valerie Barnett, Attorney-in-Fact

Key filing fact

Philippe Busque filed Form 4 for Cytek Biosciences, Inc. (CTKB) on 21 Mar 2024.

Key facts

  • This page summarizes Philippe Busque's Form 4 filing for Cytek Biosciences, Inc. (CTKB).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 21 Mar 2024, 18:19.

Change

  • Previous filing in this sequence was filed on 08 Mar 2024.
  • Current net transaction value: -$14,264.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTKB transaction

Common Stock

Options Exercise

Transaction value
Shares
+5,464
Change %
Price
Shares after
5,464
Date
20 Mar 2024
Ownership
Direct
Footnotes
F1
CTKB transaction

Common Stock

Tax liability

Transaction value
$14,264
Shares
-2,129
Change %
-39%
Price
$6.70
Shares after
3,335
Date
20 Mar 2024
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTKB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-5,464
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Mar 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,464
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Represents the number of shares withheld by and surrendered to the Issuer on March 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

Footnote F3

The shares subject to the RSU Award vested on March 20, 2024.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .